Stephen B. Hanauer

Research interests

Publications

• Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis

  New England Journal of Medicine · 2021 · https://doi.org/10.1056/nejmoa2033617

• Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn’s Disease After Ileocolonic Resection

  Gastroenterology · 2016 · 10.1053/j.gastro.2016.02.072

• Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

  New England Journal of Medicine · 2016 · https://doi.org/10.1056/nejmoa1602773

• Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis

  New England Journal of Medicine · 2016 · 10.1056/nejmoa1513248

• Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions

  Clinical Gastroenterology and Hepatology · 2015 · https://doi.org/10.1016/j.cgh.2015.06.001

• Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target

  The American Journal of Gastroenterology · 2015 · https://doi.org/10.1038/ajg.2015.233

• Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed

  Gastroenterology · 2014 · https://doi.org/10.1053/j.gastro.2014.05.008

• Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis

  New England Journal of Medicine · 2013 · 10.1056/nejmoa1215734

• Reliability and Initial Validation of the Ulcerative Colitis Endoscopic Index of Severity

  Gastroenterology · 2013 · 10.1053/j.gastro.2013.07.024

• Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial

  Gut · 2011 · 10.1136/gut.2010.221127

• Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)

  Gut · 2011 · 10.1136/gutjnl-2011-300486

• Efficacy of Biological Therapies in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis

  The American Journal of Gastroenterology · 2011 · 10.1038/ajg.2011.73

• Assessing Response and Loss of Response to Biological Therapies in IBD

  The American Journal of Gastroenterology · 2011 · 10.1038/ajg.2011.103

• The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response?

  The American Journal of Gastroenterology · 2010 · 10.1038/ajg.2010.392

• Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab

  Annals of Internal Medicine · 2007 · 10.7326/0003-4819-146-12-200706190-00159

• Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease

  Gastrointestinal Endoscopy · 2006 · 10.1016/j.gie.2005.08.011

• Human Anti–Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the CLASSIC-I Trial

  Gastroenterology · 2006 · 10.1053/j.gastro.2005.11.030

• Delayed-Release Oral Mesalamine at 4.8 g/day (800 mg tablet) for the Treatment of Moderately Active Ulcerative Colitis: The ASCEND II Trial

  The American Journal of Gastroenterology · 2005 · 10.1111/j.1572-0241.2005.00248.x

• Inflammatory bowel disease: Epidemiology, pathogenesis, and therapeutic opportunities

  Inflammatory Bowel Diseases · 2005 · 10.1097/01.mib.0000195385.19268.68

• Natalizumab Induction and Maintenance Therapy for Crohn's Disease

  New England Journal of Medicine · 2005 · 10.1056/nejmoa043335

• Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease

  Gastroenterology · 2004 · 10.1053/j.gastro.2003.11.014

• Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease

  Clinical Gastroenterology and Hepatology · 2004 · 10.1016/s1542-3565(04)00238-1

• Fecal Lactoferrin Is A Sensitive and Specific Marker in Identifying Intestinal Inflammation

  The American Journal of Gastroenterology · 2003 · 10.1111/j.1572-0241.2003.07458.x

• Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

  The Lancet · 2002 · 10.1016/s0140-6736(02)08512-4

• Inflammatory Bowel Disease

  New England Journal of Medicine · 1996 · 10.1056/nejm199603283341307

Current projects

No projects listed.